Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials

Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the reduction of ischaemic events in patients with acute coronary syndrome (ACS). However, this comes at the expense of increased bleeding. A guided selection of P2Y12 inhibiting therapy has the potential to overcome this l...

Full description

Saved in:

Bibliographic Details
Published in:	European heart journal Vol. 43; no. 10; p. 959
Main Authors:	Galli, Mattia, Benenati, Stefano, Franchi, Francesco, Rollini, Fabiana, Capodanno, Davide, Biondi-Zoccai, Giuseppe, Vescovo, Giovanni Maria, Cavallari, Larisa H, Bikdeli, Behnood, Ten Berg, Jurrien, Mehran, Roxana, Gibson, Charles Michael, Crea, Filippo, Pereira, Naveen L, Sibbing, Dirk, Angiolillo, Dominick J
Format:	Journal Article
Language:	English
Published:	England 07.03.2022
Subjects:	Acute Coronary Syndrome Humans Percutaneous Coronary Intervention Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Prasugrel Hydrochloride - adverse effects Prasugrel Hydrochloride - therapeutic use Purinergic P2Y Receptor Antagonists - adverse effects Purinergic P2Y Receptor Antagonists - therapeutic use Randomized Controlled Trials as Topic Ticagrelor - adverse effects Ticagrelor - therapeutic use Treatment Outcome Antiplatelet therapy Prasugrel P2Y12 inhibitors Platelet function Clopidogrel Genetic testing Acute coronary syndrome Ticagrelor
ISSN:	1522-9645, 1522-9645
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!